In evaluating scenarios for its business after a 2007 management buyout, Pharmalucence managers considered the impact on employment.
“We were at the bottom of the recession where jobs were being lost; we didn’t want to be part of that,” President Glenn Alto said in a presentation “Making It Massachusetts” at Interphex.
Outsourcing pharmaceutical production—one of the options considered—would downsize the firm by more than 50 employees.